Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointments of ...
Relay Therapeutics (RLAY) announces the acquisition of ZebiAI, a pioneer in applying massive experimental DNA encoded library data sets to power machine learning for drug discovery (ML-DEL).As per the terms, RLAY will pay $85M upfront, comprised of $20M in cash and $65M in RLAY common stock.Z...
Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library of industry-leadi...
Relay Therapeutics (RLAY): FY GAAP EPS of -$5.40 misses by $0.96.Revenue of $82.65MCash, cash equivalents and marketable securities of $678.1M.Press Release For further details see: Relay Therapeutics EPS misses by $0.96
Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021 Entered into a global collaboration with Genentech for the development and commercialization of RLY-197...
Finding the next Amazon is the holy grail and an epic quest for any growth oriented investor. The reality however is that the journey to that goal is primarily littered with shattered portfolios and broken dreams. I am taking a slightly different approach. By picking trends poised...
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced that preclinical data for RLY-4008, a po...
Relay Therapeutics stock has fallen from a price of $62 in mid-January, to $41.3 at the time of writing. The data-driven drug developer is slowly becoming a clinical-stage biotech with three assets in development - one in partnership with Genentech. Its targets are attractive - th...
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11, 2021 at 3:30 p.m. ET. The fireside chat will be webcast live and may be a...
Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock. The company has the platform potential to expand their pipeline to a wide-range of protein therapeutics for cancer an...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transfo...
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial res...
2024-04-24 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...